5.02MMarket Cap-172P/E (TTM)
1.6700High1.3800Low82.52KVolume1.3800Open1.3800Pre Close128.60KTurnover3.08%Turnover RatioLossP/E (Static)3.10MShares13.500052wk High0.95P/B4.34MFloat Cap1.350052wk Low--Dividend TTM2.68MShs Float528.5000Historical High--Div YieldTTM21.01%Amplitude1.3500Historical Low1.5580Avg Price1Lot Size
TFF Pharmaceuticals Stock Forum
TFF Pharmaceuticals Provides Continued Positive Outcomes From Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals, Cleveland Clinic Partner To Advance Multiple Multivalent Universal Influenza Vaccines To Protect Against Seasonal, Pandemic Viruses Into Preclinical Testing
NEWS
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals announced an update on its Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. The trial has accelerated patient enrollment with 10 patients currently enrolled. All 6 patients who completed the 12-week treatment have opted to continue to the safety extension...
NEWS
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
No comment yet